Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Sep
10
Today In Oncology
NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
SUO/AUA Updates Guidelines for Non-Muscle Invasive Bladder Cancer
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
Early ctDNA Molecular Response May Predict Outcomes With Azenosertib in Ovarian Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo